Albumin concentration significantly impacts on free teicoplanin plasma concentrations in non-critically ill patients with chronic bone sepsis

被引:45
作者
Brink, A. J. [1 ]
Richards, G. A. [2 ]
Lautenbach, E. E. G. [3 ]
Rapeport, N. [4 ]
Schillack, V. [5 ]
van Niekerk, L. [6 ]
Lipman, J. [7 ,8 ]
Roberts, J. A. [7 ,8 ,9 ]
机构
[1] Milpark Hosp, Ampath Natl Lab Serv, ZA-2193 Johannesburg, South Africa
[2] Univ Witwatersrand, Charlotte Maxeke Johannesburg Acad Hosp, Fac Hlth Sci, Dept Crit Care, Johannesburg, South Africa
[3] Milpark Hosp, Dept Orthopaed Surg, ZA-2193 Johannesburg, South Africa
[4] Milpark Hosp, Dept Med, ZA-2193 Johannesburg, South Africa
[5] Analyt Toxicol Lab Serv, George, South Africa
[6] Natl Referral Lab, Dept Esoter Sci, Ampath Natl Lab Serv, Centurion, South Africa
[7] Univ Queensland, Burns Trauma & Crit Care Res Ctr, Brisbane, Qld, Australia
[8] Royal Brisbane & Womens Hosp, Dept Intens Care Med, Herston, Qld, Australia
[9] Royal Brisbane & Womens Hosp, Dept Pharm, Brisbane, Qld, Australia
基金
英国医学研究理事会;
关键词
Teicoplanin; Protein binding; Free; Hypoalbuminaemia; Population pharmacokinetics; TDM; PROTEIN-BINDING; HOSPITALIZED-PATIENTS; PHARMACOKINETICS; HYPOALBUMINEMIA; VARIABILITY; GUIDELINES; SERUM;
D O I
10.1016/j.ijantimicag.2015.01.015
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
The impact of decreased serum albumin concentrations on free antibiotic concentrations in non-critically ill patients is poorly described. This study aimed to describe the pharmacokinetics of a high-dose regimen of teicoplanin, a highly protein-bound antibiotic, in non-critically ill patients with hypoalbuminaemia. Ten patients with chronic bone sepsis and decreased serum albumin concentrations (<35 g/L) receiving teicoplanin 12 mg/kg 12-hourly intravenously for 48 h followed by 12 mg/kg once daily were enrolled. Surgical debridement was performed on Day 3. Samples of venous blood were collected pre-infusion and post-infusion during the first 4 days of therapy. Total and free teicoplanin concentrations were assayed using validated chromatographic methods. The median serum albumin concentration for the cohort was 18 (IQR 15-24) g/L. After 48 h, the median (IQR) free trough (fC(min)) and total trough (tC(min)) concentrations were 2.90 (2.67-3.47) mg/L and 15.54 (10.28-19.12) mg/L, respectively, although trough concentrations declined thereafter. Clearance of the free concentrations was significantly high relative to the total fraction at 38.6 (IQR 29.9-47.8) L/h and 7.0 (IQR 6.8-9.8) L/h, respectively (P < 0.001). Multiple linear regression analysis demonstrated that whereas total teicoplanin concentration did not impact on free concentrations (P = 0.174), albumin concentration did (P < 0.001). This study confirms the significant impact of hypoalbuminaemia on free concentrations of teicoplanin in non-critically ill patients, similar to that in critically ill patients. Furthermore, the poor correlation with total teicoplanin concentration suggests that therapeutic drug monitoring of free concentrations should be used in these patients. (C) 2015 Elsevier B.V. and the International Society of Chemotherapy. All rights reserved.
引用
收藏
页码:647 / 651
页数:5
相关论文
共 15 条
[1]   Pharmacokinetics of once-daily dosing of ertapenem in critically ill patients with severe sepsis [J].
Brink, A. J. ;
Richards, G. A. ;
Schillack, V. ;
Kiem, S. ;
Schentag, J. .
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2009, 33 (05) :432-436
[2]   Recommendations to achieve rapid therapeutic teicoplanin plasma concentrations in adult hospitalised patients treated for sepsis [J].
Brink, A. J. ;
Richards, G. A. ;
Cummins, R. R. ;
Lambson, J. .
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2008, 32 (05) :455-458
[4]   Development of teicoplanin dosage guidelines for patients treated within an outpatient parenteral antibiotic therapy (OPAT) programme [J].
Lamont, Elspeth ;
Seaton, R. Andrew ;
Macpherson, Merran ;
Semple, Lindsay ;
Bell, Emma ;
Thomson, Alison H. .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2009, 64 (01) :181-187
[5]   Steady-state trough serum and epithelial lining fluid concentrations of teicoplanin 12 mg/kg per day in patients with ventilator-associated pneumonia [J].
Mimoz, O ;
Rolland, D ;
Adoun, M ;
Marchand, S ;
Breilh, D ;
Brumpt, I ;
Debaene, B ;
Couet, W .
INTENSIVE CARE MEDICINE, 2006, 32 (05) :775-779
[6]   Antiepileptic drugs - best practice guidelines for therapeutic drug monitoring: A position paper by the subcommission on therapeutic drug monitoring, ILAE Commission on Therapeutic Strategies [J].
Patsalos, Philip N. ;
Berry, David J. ;
Bourgeois, Blaise F. D. ;
Cloyd, James C. ;
Glauser, Tracy A. ;
Johannessen, Svein I. ;
Leppik, Ilo E. ;
Tomson, Torbjoern ;
Perucca, Emilio .
EPILEPSIA, 2008, 49 (07) :1239-1276
[7]   The effect of multifactorial, multidisciplinary educational interventions on appropriate use of teicoplanin [J].
Pea, Federico ;
Viale, Pierluigi ;
Pavan, Federica ;
Tavio, Marcello ;
Poz, Donatella ;
Beltrame, Anna ;
Furlanut, Mario .
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2006, 27 (04) :344-350
[8]   Variability in protein binding of teicoplanin and achievement of therapeutic drug monitoring targets in critically ill patients: Lessons from the DALI Study [J].
Roberts, J. A. ;
Stove, V. ;
De Waele, J. J. ;
Sipinkoski, B. ;
McWhinney, B. ;
Ungerer, J. P. J. ;
Akova, M. ;
Bassetti, M. ;
Dimopoulos, G. ;
Kaukonen, K. -M. ;
Koulenti, D. ;
Martin, C. ;
Montravers, P. ;
Rellom, J. ;
Rhodes, A. ;
Starr, T. ;
Wallis, S. C. ;
Lipman, J. .
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2014, 43 (05) :423-430
[9]   Altered Pharmacokinetics of Piperacillin in Febrile Neutropenic Patients with Hematological Malignancy [J].
Sime, Fekade Bruck ;
Roberts, Michael S. ;
Warner, Morgyn S. ;
Hahn, Uwe ;
Robertson, Thomas A. ;
Yeend, Sue ;
Phay, Andy ;
Lehman, Sheila ;
Lipman, Jeffrey ;
Peake, Sandra L. ;
Roberts, Jason A. .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2014, 58 (06) :3533-3537
[10]   Teicoplanin population pharmacokinetic analysis in hospitalized patients [J].
Soy, Dolors ;
Lopez, Ester ;
Ribas, Josep .
THERAPEUTIC DRUG MONITORING, 2006, 28 (06) :737-743